Discounting health effects in pharmacoeconomic evaluations: current controversies.
作者信息
Birks Stuart
出版信息
Pharmacoeconomics. 2006;24(12):1273-4; author reply 1275-6. doi: 10.2165/00019053-200624120-00009.
Abstract
摘要
相似文献
1
Discounting health effects in pharmacoeconomic evaluations: current controversies.
Pharmacoeconomics. 2006;24(12):1273-4; author reply 1275-6. doi: 10.2165/00019053-200624120-00009.
2
Discounting health effects in pharmacoeconomic evaluations: current controversies.药物经济学评价中对健康影响的贴现：当前争议
Pharmacoeconomics. 2005;23(7):639-49. doi: 10.2165/00019053-200523070-00001.
3
Double counting and the reporting of cost per event avoided.
Clin Ther. 2006 Apr;28(4):602-3. doi: 10.1016/j.clinthera.2006.04.002.
4
Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values.质量调整生命年作为决策者工具，以解决治疗所需人数/伤害值固有的局限性。
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):99-102. doi: 10.1586/erp.09.10.
5
The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit.一项药物经济学研究的结果：增量成本效益比与净货币效益
Heart. 2017 Nov;103(21):1746. doi: 10.1136/heartjnl-2017-311816.
6
[Methods for analyzing uncertainty].[分析不确定性的方法]
Farm Hosp. 2011 May;35 Suppl 2:3-9. doi: 10.1016/S1130-6343(11)70016-2.
7
Pharmacoeconomics.药物经济学
J Assoc Physicians India. 2002 Aug;50:1057-62.
8
Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.药物经济学研究中的统计分析。当前问题与标准综述。
Pharmacoeconomics. 1996 Jun;9(6):506-16. doi: 10.2165/00019053-199609060-00005.
9
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.荷兰和苏格兰孤儿药申报监管建议回顾：重点关注潜在的药物经济学评估。
Clin Ther. 2010 Aug;32(9):1651-61. doi: 10.1016/j.clinthera.2010.08.006.
10
Pharmacoeconomic research.
Pharm World Sci. 2003 Dec;25(6):245-6. doi: 10.1023/b:phar.0000006525.10662.50.
引用本文的文献
1
Differential time preferences for money and quality of life.对金钱和生活质量的差异时间偏好。
Pharmacoeconomics. 2014 Apr;32(4):411-9. doi: 10.1007/s40273-013-0124-8.
本文引用的文献
1
Should patients have a greater role in valuing health states?患者在评估健康状态方面是否应发挥更大作用？
Appl Health Econ Health Policy. 2005;4(4):201-8. doi: 10.2165/00148365-200504040-00002.
2
Severity of illness and priority setting: worrisome lack of discussion of surprising finding.疾病严重程度与优先级设定：令人担忧的是，对惊人发现缺乏讨论。
J Health Econ. 2006 Jan;25(1):170-2; discussion 173-4. doi: 10.1016/j.jhealeco.2005.09.001. Epub 2005 Oct 6.
3
Discounting health effects in pharmacoeconomic evaluations: current controversies.药物经济学评价中对健康影响的贴现：当前争议
Pharmacoeconomics. 2005;23(7):639-49. doi: 10.2165/00019053-200523070-00001.
Zotero 插件